Bacteria, genetics and irritable bowel syndrome

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 3, 2010, Pages 271-276

  Craig, Orla F ^a   Quigley, Eamonn M M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Cytokine; E cadherin; Gastroenteritis; Genetic; IL 6; Intestinal permeability; Irritable bowel syndrome

Indexed keywords

INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; UVOMORULIN;

ACUTE GASTROENTERITIS; BACTERIAL INFECTION; CAMPYLOBACTER JEJUNI; CAUCASIAN; CDH1 GENE; EPIDEMIC; ESCHERICHIA COLI O157; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; IL6 GENE; IMMUNE RESPONSE; IMMUNOGENETICS; IRRITABLE COLON; MARKER GENE; NOTE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TLR9 GENE;

EID: 77953274740     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.31     Document Type: Note

References (60)

1. Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis. 15, 237-241 (2006).
2. Bommelaer G, Poynard T, Le Pen C et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol. Clin. Biol. 28, 554-561 (2004).
3. Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern. Med. J. 36, 28-36 (2006).
4. Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br. Med. J. 304, 87-90 (1992).
5. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101, 927-934 (1991).
6. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br. J. Gen. Pract. 54, 495-502 (2004).
7. Wilson A, Longstreth GF, Knight K et al. Quality of life in managed care patients with irritable bowel syndrome. Manag. Care Interface 17, 24-28, 34 (2004).
8. Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 38, 1569-1580 (1993).
9. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther. 17, 643-650 (2003).
10. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 24, 21-37 (2006).
11. Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J. Gastroenterol. 14, 2639-2649 (2008).
12. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 124, 1662-1671 (2003).
13. Longstreth GF, Hawkey CJ, Mayer EA et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment. Pharmacol. Ther. 15, 959-964 (2001).
14. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 53, 1096-1101 (2004).
15. Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 44, 400-406 (1999).
16. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br. Med. J. 314, 779-782 (1997).
17. Mearin F, Perez-Oliveras M, Perello A et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 129, 98-104 (2005).
18. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 51, 410-413 (2002).
19. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 131, 445-450; quiz 660 (2006).
20. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1b in recently acquired post-infectious irritable bowel syndrome. Gut 52, 523-526 (2003).
21. Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 347, 150-153 (1996).
22. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol. 98, 1578-1583 (2003).
23. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47, 804-811 (2000).
24. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 132, 913-920 (2007).
25. Dinan TG, Clarke G, Quigley EM et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am. J. Gastroenterol. 103, 2570-2576 (2008).
26. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551 (2005).
27. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther. 20, 1317-1322 (2004).
28. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 27, 37-40 (1986).
29. Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ 3rd. Familial association in adults with functional gastrointestinal disorders. Mayo Clin. Proc. 75, 907-912 (2000).
30. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 121, 799-804 (2001).
31. Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment. Pharmacol. Ther. 25, 1343-1350 (2007).
32. Dinan TG, Cryan J, Shanahan F, Keeling PWN, Quigley EMM. Irritable bowel syndrome: an epigenetic perspective. Nat. Rev. Gastroenterol. (In press).
33. Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, Del Tacca M. The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol. Med. 14, 295-304 (2008).
34. Kim HJ, Camilleri M, Carlson PJ et al. Association of distinct a2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 53, 829-837 (2004).
35. Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am. J. Gastroenterol. 97, 1780-1784 (2002).
36. Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment. Pharmacol. Ther. 26, 979-986 (2007).
37. Camilleri M. Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. Dig. Dis. Sci. 54, 2318-2324 (2009).
38. Quigley EMM. Functional gastrointestinal disorders; has the genomic era arrived? Gastroenterology 126, 1193-1195 (2004).
39. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 138, 1276-1285 (2010).
40. Richards A. The Walkerton Health Study. Can. Nurse 101, 16-21 (2005).
41. Wu S, Rhee KJ, Zhang M, Franco A, Sears CL. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and g-secretase-dependent E-cadherin cleavage. J. Cell Sci. 120, 1944-1952 (2007).
42. Frank CF, Hostetter MK. Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans. Transl. Res. 149, 211-222 (2007).
43. Barbara G. Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am. J. Gastroenterol. 101, 1295-1298 (2006).
44. Houlston RS, Webb E, Broderick P et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet. 40, 1426-1435 (2008).
45. Barrett JC, Lee JC, Lees CW et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet. 41, 1330-1334 (2009).
46. Muise AM, Walters TD, Glowacka WK et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut 58, 1121-1127 (2009).
47. Clarke G, Quigley EMM, Cryan JF, Dinan TG. Irritable bowel syndrome: towards biomarker identification. Trends Mol. Med. 15, 478-489 (2009).
48. Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 133, 799-807 (2007).
49. Villani AC, Saito AY, Lemire M et al. Validation of genetic risk factors for post-infectious irritable bowel syndrome (IBS) in patients with sporadic IBS. Gastroenterology 136(5 Suppl. 1), A-68 (2009).
50. Wang BM, Wang YM, Zhang WM et al. [Serotonin transporter gene polymorphism in irritable bowel syndrome]. Zhonghua Nei Ke Za Zhi 43, 439-441 (2004).
51. Park JM, Choi MG, Park JA et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol. Motil. 18, 995-1000 (2006).
52. Odunsi ST, Camilleri M, Bharucha AE et al. Reproducibility and performance characteristics of colonic compliance, tone, and sensory tests in healthy humans. Dig. Dis. Sci. 55, 709-715 (2010).
53. Camilleri M, Carlson P, McKinzie S et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G13-G19 (2008).
54. Melum E, Franke A, Karlsen TH. Genome-wide association studies - a summary for the clinical gastroenterologist. World J. Gastroenterol. 15, 5377-5396 (2009).
55. Dinan TG, Clarke G, Quigley EM et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am. J. Gastroenterol. 103, 2570-2576 (2008).
56. Scully P, McKernan DP, Keohane J et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am. J. Gastroenterol. DOI: 10.1038/ajg.2010.159 (2010) (Epub ahead of print).
57. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum. Psychopharmacol. 19, 397-403 (2004).
58. Keita AV, Soderholm JD, Ericson AC. Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells. Neurogastroenterol. Motil. DOI: 10.1111/j.1365-2982.2010.01471.x (2010) (Epub ahead of print).
59. Keita AV, Söderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol. Motil. DOI: 10.1111/j.1365-2982.2010. 01498.x (2010) (Epub ahead of print).
60. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 298(6), G807-G819 (2010).